WHAT IS CLAIMED IS:

1. A combination therapy comprising a conjugate compound or pharmaceutically acceptable salt thereof and an immunotherapy for use in the treatment of a Sortilin-expressing cancer, wherein the conjugate compound has the formula of A-$(B)_n$, wherein

A is a peptide compound of 30 residues or less comprising an amino acid sequence having at least 60% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 10, 1-9 and 11-13:

GVRAKAGVRN(Nle)FKSESY	(SEQ ID NO: 10)
$X_1X_2X_3X_4X_5GVX_6AKAGVX_7NX_8FKSESY$	(SEQ ID NO: 1)
$(X_9)_nGVX_{10}AKAGVX_{11}NX_{12}FKSESY$	(SEQ ID NO: 2)
$YKX_{13}LRRX_{14}APRWDX_{15}PLRDPALRX_{16}X_{17}L$	(SEQ ID NO: 3)
$YKX_{18}LRR(X_{19})_NPLRDPALRX_{20}X_{21}L$	(SEQ ID NO: 4)
IKLSGGVQAKAGVINMDKSESM	(SEQ ID NO: 5)
IKLSGGVQAKAGVINMFKSESY	(SEQ ID NO: 6)
IKLSGGVQAKAGVINMFKSESYK	(SEQ ID NO: 7)
GVQAKAGVINMFKSESY	(SEQ ID NO: 8)
GVRAKAGVRNMFKSESY	(SEQ ID NO: 9)
YKSLRRKAPRWDAPLRDPALRQLL	(SEQ ID NO: 11)
YKSLRRKAPRWDAYLRDPALRQLL	(SEQ ID NO: 12)
YKSLRRKAPRWDAYLRDPALRPLL	(SEQ ID NO: 13)

wherein

X_1, X_2, X_3, X_4, X_5, X_6, X_7, X_8, X_9, X_{10}, X_{11}, X_{12}, X_{13}, X_{14}, X_{15}, X_{18} and X_{19} are independently chosen from any amino acid;

X_{16}, X_{17}, X_{20} and X_{21} are independently chosen from Q, P, Y, I and L;

n is 0, 1, 2, 3, 4 or 5;

when X_9 is present more than once, each of said X_9 is independently chosen from any amino acid;

when X_{19} is present more than once, each of said X_9 is independently chosen from any amino acid,

optionally the peptide compound is cyclic,

B is at least one antitumor agent, wherein B is connected to A directly or via a linker.

2. The combination therapy for use according to claim 1, wherein the peptide compound comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 10, 1-9 and 11-13.

3. The combination therapy for use according to claim 1 or 2, wherein the peptide compound comprises the amino acid sequence of any one of SEQ ID NOs: 10, 1-9 and 11-13, and further comprises 1 to 3 additional amino acids at its amino- and/or carboxy-terminal end.

4. The combination therapy for use according to claim 3, wherein the peptide compound comprises a cysteine residue at its amino- and/or carboxy-terminal end.

5. The combination therapy for use according to claim 4, wherein the peptide compound comprises one of the following amino acid sequences:

Z_1GVRAKAGVRN(Nle)FKSESYZ_2 (SEQ ID NO:43)
$Z_1X_1X_2X_3X_4X_5$GVX_6AKAGVX_7NX_8FKSESYZ_2 (SEQ ID NO:34)
$Z_1(X_9)_n$GVX_{10}AKAGVX_{11}NX_{12}FKSESYZ_2 (SEQ ID NO:35)
Z_1YkX_{13}LRRX_{14}APRWDX_{15}PLRDPALR$X_{16}X_{17}$LZ_2 (SEQ ID NO:36)
Z_1YKX_{18}LRR$(X_{19})_N$PLRDPALR$X_{20}X_{21}$LZ_2 (SEQ ID NO:37)
Z_1IKLSGGVQAKAGVINMDKSESMZ_2 (SEQ ID NO:38)
Z_1IKLSGGVQAKAGVINMFKSESYZ_2 (SEQ ID NO:39)
Z_1IKLSGGVQAKAGVINMFKSESYKZ_2 (SEQ ID NO:40)
Z_1GVQAKAGVINMFKSESYZ_2 (SEQ ID NO:41)
Z_1GVRAKAGVRNMFKSESYZ_2 (SEQ ID NO:42)
Z_1YKSLRRKAPRWDAPLRDPALRQLLZ_2 (SEQ ID NO:44)
Z_1YKSLRRKAPRWDAYLRDPALRQLLZ_2 (SEQ ID NO:45)
Z_1YKSLRRKAPRWDAYLRDPALRPLL Z_2 (SEQ ID NO:46),

wherein X_1-X_{21} are as defined in claim 1; Z_1 is a cysteine residue or is absent; Z_2 is a cysteine residue or is absent, and at least one of Z_1 and Z_2 is present.

6. The combination therapy for use according to claim 1 or 5, wherein the peptide compound comprises the amino acid sequence of SEQ ID NO: 10.

7. The combination therapy for use according to any one of claims 1 to 6, wherein the peptide compound comprises at least one modifying group, such as acetyl or succinyl, at its amino- and/or carboxy-terminal end.

8. The combination therapy for use according to claim 1, wherein the peptide compound is represented by SEQ ID NO:15, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, or SEQ ID NO:48:

Acetyl-GVRAKAGVRN(Nle)FKSESY	(SEQ ID NO: 15)
Acetyl-GVRAKAGVRNMFKSESY	(SEQ ID NO: 14)
Acetyl-YKSLRRKAPRWDAPLRDPALRQLL	(SEQ ID NO: 16)
Acetyl-YKSLRRKAPRWDAYLRDPALRQLL	(SEQ ID NO: 17)
Acetyl-YKSLRRKAPRWDAYLRDPALRPLL	(SEQ ID NO: 18)
Acetyl-GVRAKAGVRN(Nle)FKSESYC	(SEQ ID NO: 48).

9. The combination therapy for use according to claim 1, wherein the conjugate is represented by SEQ ID NO:23 or SEQ ID NO:22:

Acetyl-GVRAK(J^1)AGVRN(Nle)FK(J^2)SESY	(SEQ ID NO:23);
GVRAK(J^1)AGVRN(Nle)FK(J^2)SESY	(SEQ ID NO:22);

wherein J^1 and J^2 are each independently a therapeutic agent attached to a lysine (K) residue.

10. The combination therapy for use according to any one of claims 1 to 9, wherein the antitumor agent is a radionuclide or a chemotherapeutic agent, for example docetaxel.

11. The combination therapy for use according to any one of claims 1 to 10, wherein the immunotherapy comprises immune checkpoint inhibitor (ICI) therapy.

12. The combination therapy for use according to claim 11, wherein the ICI is a Programmed cell death-1 (PD-1) inhibitor, a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, or a Programmed death-ligand 1 (PD-L1) inhibitor.

13. The combination therapy for use according to claim 12, wherein the ICI is a PD-L1 inhibitor.

14. The combination therapy for use according to any one of claims 1 to 13, wherein the cancer is an immunologically cold cancer.

15. The combination therapy for use according to any one of claims 1 to 14, wherein the cancer is brain cancer, pancreatic cancer, ovarian cancer, breast cancer, endometrial cancer, thyroid cancer, lung cancer, prostate cancer or melanoma.